Suzhou Zion Pharma Technology Co Ltd. has identified KRAS inhibitors, in particular GTPase KRAS G12D mutant and/or G13D mutant, reported to be useful for the treatment of cancer.

The Ohio State University has synthesized dual specificity protein kinase TTK (MPS1; MPS1L1) inhibitors reported to be useful for the treatment of cancer.

Stanford University has disclosed leucine-rich repeat kinase 2 (LRRK2; dardarin) inhibitors reported to be useful for the treatment of cancer, Crohn’s disease, leprosy, neurodegeneration, immunological disorders, Parkinson’s disease and Alzheimer’s disease.

Insilico Medicine Ltd. has described glucocorticoid receptor (GR) antagonists reported to be useful for the treatment of Cushing’s syndrome, Addison’s disease, osteoporosis, rheumatoid arthritis, asthma, rhinitis, allergy and skin lesions.

Innovstone Therapeutics Ltd. has divulged prodrugs of deuterated baloxavir marboxil derivatives acting as polymerase basic protein 2 (PB2) (influenza virus) inhibitors reported to be useful for the treatment of influenza A, influenza B and influenza C viral infections.

Jiangsu Vcare Pharmatech Co. Ltd. has identified S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors reported to be useful for the treatment of cancer.

Zhejiang University has synthesized isoquinoline derivatives reported to be useful for the treatment of cancer, infections, autoimmune disease, and cardiovascular, cerebrovascular and Inflammatory disorders.

LG Chem Ltd. has disclosed bromodomain-containing protein 4 (BD1 domain) (BRD4 BD1) and CREB-binding protein (CREBBP; CBP) inhibitors reported to be useful for the treatment of cancer, inflammatory disorders and autoimmune disease.

Temple University has described compounds acting as antioxidants and nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators reported to be useful for the treatment of Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, cerebral palsy, epilepsy and multiple sclerosis.

Chengdu Chipscreen Pharmaceutical Ltd. has divulged Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.